The removal of sFlt-1 from the circulation by apheresis has shown promising results as a potential treatment of preeclampsia, since increases the levels of free VEGF and PlGF in serum samples of preeclamptic patients (Matin et al., 2020). The gene discussed is VEGFA; the disease is preeclampsia.